Generalized anxiety disorder

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 343-362

  Hidalgo, Rosario B ^a   Sheehan, David V ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861133727     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00019-X     Document Type: Chapter

References (182)

1. Abelson J.L., Glitz D., Cameron O.G., et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991, 48:157-162.
2. Allgulander C. Generalized anxiety disorder: between now and DSM-V. Psychiatr Clin North Am 2009, 32:611-628.
3. Allgulander C., Bandelow B., Hollander E., et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003, 8:53-61.
4. Allgulander C., Florea I., Trap Huusom A.K. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2008, 23:519-526.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1980, American Psychiatric Press, Washington, DC. 3rd edn.
6. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Press, Washington, DC. 3rd edn, revised.
7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington, DC. 4th edn.
8. Andrews G., Slade T. The classification of anxiety disorders in ICD-10 and DSM-IV: a concordance analysis. Psychopathology 2002, 35:100-106.
9. Angst J., Gamma A., Baldwin D.S., et al. The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 2009, 259:37-45.
10. Ansseau M., Fischler B., Dierick M., et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study. Eur Psychiatry 2005, 20:229-235.
11. Avery D.H., Osgood T.B., Ishiki D.M., et al. The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am J Psychiatry 1985, 142:844-848.
12. Baldwin D.S., Anderson I.M., Nutt D.J., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Clin Psychiatry 2001, 62:53-58.
13. Ballenger J.C., Davidson J.R., Lecrubier Y. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001, 62:53-58.
14. Bandelow B., Zohar J., Hollander E., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders: first revision. World J Biol Psychiatry 2008, 9:248-312.
15. Barger S.D., Sydeman S.J. Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorders?. J Affect Disord 2005, 88:87-91.
16. Barlow G.W., Blanchard E.B., Vermilyea J.A., et al. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry 1986, 143:40-44.
17. Barlow D.H. Anxiety and its disorders: the nature and treatment of anxiety and panic 1988, Guilford Press, New York.
18. Beesdo K., Lau J.Y.F., Guyer A.E., et al. Common and distinct amygdala-function perturbations in depressed vs anxious adolescents. Arch Gen Psychiatry 2009, 3:275-285.
19. Belleville G., Bélanger L., Ladouceur R., et al. Sensitivity and specificity of the Worry and Anxiety Questionnaire (WAQ) in a sample of health-care users in the province of Quebec. Encephale 2008, 34:240-248.
20. Blazer D.G., Hughes D.C., George L.K., et al. Generalized anxiety disorder. Psychiatric Disorder in America 1991, 180-203. The Free Press, Macmillan, New York. L.N. Robins, D.A. Regier (Eds.).
21. Bond A.J., Winegrove J., Curran H., et al. Treatment of generalized anxiety disorder with a short course of psychological treatment combined with buspirone or placebo. J Affect Disord 2002, 72:267-271.
22. Borkovec T.D., Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993, 61:611-619.
23. Borkovec T.D., Ruscio A.M. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001, 62:37-42.
24. Borkovec T.D., Whisman M.A. Psychosocial treatment for GAD. Long-Term Treatment for the Anxiety Disorders 1996, 171-199. American Psychiatric Press, Washington, DC. M. Mavissakalian, R.F. Prien (Eds.).
25. Brawman-Mintzer O., Lydiard R.B., Emmanuel N., et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry 1993, 150:1216-1218.
26. Brawman-Mintzer O., Knapp R.G., Nietert P.J. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005, 66:1321-1325.
27. Brenes G.A. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003, 65:963-970.
28. Brewerton T.D., Lydiard R.B., Johnson M.R., et al. CSF serotonin: diagnostic and seasonal differences. New Research and Abstracts of the 148th Meeting of the American Psychiatric Association 1995, 151. American Psychiatric Press, Washington, DC,, abstract NR385.
29. Brown T.A., Barlow D.H. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 1992, 60:835-844.
30. Butler G., Cullington A., Hibbert G., et al. Anxiety management for persistent generalized anxiety. Br J Psychiatry 1987, 151:535-542.
31. Cameron O.G., Smith C.B., Lee M.A., et al. Adrenergic status in anxiety disorders: platelet alpha two-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and normal subjects. Biol Psychiatry 1990, 28:3-20.
32. Carroll B.J., Davidson J.R.T. Screening Scale for DSM-IV GAD 2000, Copyright.
33. Carter C.S., Krug M.K. Editorial: the functional neuroanatomy of dread: functional magnetic resonance imaging insights into generalized anxiety disorder and its treatment. Am J Psychiatry 2009, 166:263-265.
34. Charney D.S., Woods S.W., Heninger G.R., et al. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 1989, 27:173-182.
35. Cho M.J., Kim J.K., Jeon H.J., et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J Nerv Ment Dis 2007, 195:203-210.
36. Chouinard G., Bandelow B., Ahokas A., et al. Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in generalized anxiety disorder: a Phase III, double-blind, placebo-controlled study 2007, 9-13 December (P25).
37. Davidson J.R.T., DuPont R.L., Hedges D., et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999, 60:528-535.
38. Davidson J., Allgulander C., Pollack M.H., et al. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized double-blind, placebo-controlled studies. Hum Psychopharmacol 2008, 23:519-526.
39. Davidson J.R., Zhang W., Connor K.M., et al. A psychopharmacological treatment algorithm for generalised anxiety disorder. J Psychopharmacol 2010, 24:3-26.
40. Davis J.M. Slow wave sleep and 5-HT2 receptor sensitivity in GAD. A pilot study with ritanserin. Psychopharmacology 1992, 108:387-389.
41. De Luca A.K., Lenze E.J., Mulsant B.H., et al. Comorbid anxiety disorder in late life depression: association with memory decline over four years. Int J Geriatr Psychiatry 2005, 20:848-854.
42. Demyttenaere K., Friis Andersen H., Reines E.H. Impact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol 2008, 23:276-288.
43. De Ruiter C., Rijken H., Garsen B., et al. Comorbidity among the anxiety disorders. J Anxiety Disord 1989, 3:57-68.
44. Durham R.C., Murphy T., Allan T., et al. Cognitive therapy, analytic psychotherapy, and anxiety management training for generalized anxiety disorder. Br J Psychiatry 1994, 165:315-323.
45. Eaker E.D., Pinsky J., Castelli W.P. Myocardial infarction and coronary death among women psychosocial predictors from a 20-year follow-up of women in the Framingham Study. Am J Epidemiol 1992, 135:854-864.
46. Eisen J.L. Course and psychosocial impairment in GAD 1998.
47. Endicott J., Nee J., Harrison W., et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993, 29:321-326.
48. Faravelli C., Deglinnocenti B.G., Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 1989, 79:308-312.
49. Fava G.A., Rafanelli C., Cazzaro M., et al. Well-being therapy: a novel psychotherapeutic approach for residual symptoms of affective disorders. Psychol Med 1998, 28:475-480.
50. Fava M., Alpert J.E., Carmin C.N., et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004, 34:1299-1308.
51. Fava G.A., Ruini C., Rafanelli C., et al. Well-being therapy of generalized anxiety disorder. Psychother Psychosom 2005, 74:26-30.
52. Fava M., Rush A.J., Alpert J.E., et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008, 165:342-351.
53. Ferrarese C., Appollonio I., Frigo M., et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 1990, 82:169-173.
54. Fisher P.L., Durham R.C. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since. Psychol Med 1999, 29:1425-1434.
55. Fogarty C.T., Sharma S., Chetty V.K., et al. Mental health conditions are associated with increased health care utilization among urban family medicine patients. J Am Board Fam Med 2008, 21:398-407.
56. Fossey M.D., Bruce Lydiard R., Ballenger J.C., et al. Cerebrospinal fluid corticotropin-releasing factor concentration in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 1996, 39:703-707.
57. Freeman M., Freeman S., McElroy S. The comorbidity of bipolar and anxiety disorders: prevalence psychobiology, and treatment issues. J Affect Disord 2002, 68:1-23.
58. Gao K., Muzina D., Gajwani P., et al. Efficacy of typical and atypical antipsychotics for the primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006, 67:1327-1340.
59. Gao K., Sheehan Calabrese JR Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009, 9:1147-1158.
60. Gatt J.M., Nemeroff C.B., Dobson-Stone C., et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathway to syndromal depression and anxiety. Mol Psychiatry 2009, 14:681-695.
61. Germine M., Goddard A.W., Woods S.W., et al. Anger and anxiety response to chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 1992, 32:437-467.
62. Goodwin R.D., Gorman J.M. Psychopharmacological treatment of generalized anxiety disorder and the risk of major depression. Am J Psychiatry 2002, 159:1935-1937.
63. Goodwin R.D., Stein M.B. Generalized anxiety disorder and peptic ulcer disease among adults in the United States. Psychosom Med 2002, 64:862-866.
64. Grant B.F., Hasin D.S., Stinson F.S., et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2005, 35:1747-1759.
65. Greenberg P.E., Sisitsky T., Kessler R.C., et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999, 60:427-435.
66. Grobin A.C., Morrow A.L. 3α-Hydroxy-5αpregnan-20-one exposure reduces GABA(A) receptor α subunit mRNA levels. Eur J Pharmacol 2000, 401:R1-R2.
67. Gros D.F., Antony M.M., McCabe R.E., et al. Frequency and severity of the symptoms of irritable bowel syndrome across anxiety disorders and depression. J Anxiety Disord 2008, 23:290-296.
68. Guillem E., Pelissolo A., Lepine J.P. Mental disorders and migraine: epidemiologic studies. Encephale 1999, 25:436-442.
69. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatry 1969, 76-79. special publ 3:.
70. Härter M.C., Conway K.P., Merikangas K.R. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 2003, 253:313-320.
71. Hazlett-Stevens H., Craske M.G., Mayer E.A., et al. Prevalence of irritable bowel syndrome among university students: the roles of worry, neuroticism, anxiety sensitivity and visceral anxiety. J Psychosom Res 2003, 55:501-505.
72. Hettema J.M., Prescott C.A., Kendler K.S. A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis 2001, 189:413-420.
73. Hettema J.M., Prescott C.A., Kendler K.S. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiatry 2004, 161:1581-1587.
74. Hidalgo R.B., Davidson J.R.T. GAD: an important clinical concern. Med Clin North Am 2001, 85:691-710.
75. Hidalgo R.B., Tupler L.A., Davidson J.R.T. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007, 21:864-872.
76. Hoehn-Saric R., McLeod D.R., Zimmerli W.D. Somatic manifestations in women with generalized anxiety disorder. Arch Gen Psychiatry 1989, 46:1113-1119.
77. Hoehn-Saric R., McLeod D.R., Lee Y.B., et al. Cortisol levels in generalized anxiety disorder. Letter. Psychiatry Res 1991, 38:313-315.
78. Hoffman D.L., Dukes E.M., Wittchen H.U. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008, 25:72-90.
79. Hughes P.H., Baldwin D.C., Conard S.E., et al. Resident physician substance use in the United States. J Am Med Assoc 1991, 265:2069-2073.
80. Hunt C., Issakidis C., Andrews G. DSM-IV generalized anxiety disorder in the Australian national survey of mental health and well-being. Psychol Med 2002, 32:649-659.
81. Iny L.J., Pecknold J., Suranyi-Cadotte B.E., et al. Studies of a neurochemical link between depression, anxiety, and stress from [3H] imipramine and [3H] paroxetine binding on human platelets. Biol Psychiatry 1994, 36:281-291.
82. Jonas B.S., Franks P., Ingram D.D. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up study. Arch Fam Med 1997, 6:43-49.
83. Joyce M., Khan A., Atkinson S., et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD) 2008, 3-8 May (New Research Abstract 3138).
84. Judd L.L., Kessler R.C., Paulus M.P., et al. Comorbidity as fundamental feature of generalized anxiety disorder: Results from the NCS. Acta Psychiatr Scand 1998, 98:6-11.
85. Katon W., Von Komoff M., Lin E.H.B. Distressed high utilizers of medical care: DSM-III diagnoses among distressed and treatment needs. Gen Hosp Psychiatry 1990, 12:355-362.
86. Katzman M., Brawman-Mintzer O., Reyes E., et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial 2008, Poster, APA, Washington, DC, May 3-8 (New Research Abstract 3140).
87. Kawachi I., Sparrow D., Vokonas P.S., et al. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 1994, 90:2225-2229.
88. Kendler K.S., Davis C.G., Kessler R.C. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br J Psychiatry 1997, 170:541-548.
89. Kendler K.S., Gardner C.O., Gatz M., et al. The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample. Psychol Med 2007, 37:453-462.
90. Kessler R., Rubinow D., Holmes C., et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997, 27:1079-1089.
91. Kessler R.C., DuPont R.L., Berglund P., et al. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 1999, 156:1915-1923.
92. Kessler R.C., Zhao S., Katz S.J., et al. Past-year use of outpatient service for psychiatric problems in the National Comorbidity Survey. Am J Psychiatry 1999, 156:115-123.
93. Kessler R.C., Chiu W.T., Demler O., et al. Prevalence, severity, and comorbidity of 12 month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602.
94. Kubzansky L.D., Kawachi I., Spiro A., et al. Is worrying bad for your heart? A prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation 1997, 95:818-824.
95. Lader M., Scotto J.C. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998, 139:402-406.
96. Lambert J.J., Belelli D., Hill-Venning C., et al. Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 1995, 16:295-303.
97. Lee S., Tsang A., Chui H., et al. A community epidemiological survey of generalized anxiety disorder in Hong Kong. Community Ment Health J 2007, 43:305-319.
98. Lee S., Tsang A., Shang M.Y., et al. Lifetime prevalence of inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol Med 2007, 37:61-71.
99. Lesch K.-P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
100. Lieb R., Becker E., Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005, 15:445-452.
101. Lipman R.S., Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. Evaluation of Psychological Therapies 1976, 178-218. Johns Hopkins University Press, Baltimore, MD. R. Spitzer, D. Klein (Eds.).
102. Löwe B., Decker O., Müller S., et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care 2008, 46:266-274.
103. Majewska M.D., Harrison N.L., Schwartz R.D., et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986, 232:1004-1007.
104. Maron E., Küikka J., Tihonen J., et al. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. Eur Arch Psychiatry Clin Neurosci 2004, 254:392-396.
105. Mathew R.J., Weinman M.L., Claghorn J.L. Anxiety and cerebral blood flow. The Biology of Anxiety 1982, 23-33. Brunner/Mazel, New York. R.J. Mathew (Ed.).
106. Mathew S.J., Mao X., Coplan J.D., et al. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study. Am J Psychiatry 2004, 161:1119-1121.
107. McElroy S., Altshuler L., Suppes T., et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001, 158:420-426.
108. McWilliams L.A., Goodwin R.D., Cox B.J. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 2004, 111:77-83.
109. Mendels J., Schless A.P. Comparative efficacy of alprazolam, imipramine and placebo administered once a day in treating depressed patients. J Clin Psychiatry 1986, 47:357-361.
110. Merideth C., Cutler A., Neijber A. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder 2008, Poster, ECNP, Barcelona, Spain.
111. Merikangas K.R., Avenevoli S., Dierker L., et al. Vulnerability factors among children at risk for anxiety disorders. Biol Psychiatry 1999, 46:1523-1535.
112. Meyer T.J., Miller M.L., Metzger R.L., et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990, 28:487-495.
113. Mittal D., Fortney J.C., Pyne J.M., et al. Impact of comorbid anxiety disorders on health-related quality of life among patients with major depressive disorder. Psychiatr Serv 2006, 57:1731-1737.
114. Moffitt T.E., Caspi A., Harrington H., et al. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. Psychol Med 2007, 37:441-452.
115. Moffitt T.E., Harrington H., Caspi A., et al. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. Arch Gen Psychiatry 2007, 64:651-660.
116. Mohlman J., Price R.B., Eldreth D.A., et al. The relation of worry to prefrontal cortex volume in older adults with and without generalized anxiety disorder. Psychiatry Res 2009, 17:121-127.
117. Monk C.S., Telzer E.H., Mogg K., et al. Amygdala and ventrolateral prefrontal cortex activation to masked angry faces in children and adolescents with generalized anxiety disorder. Arch Gen Psychiatry 2008, 65:568-576.
118. Montgomery S.A., Sheehan D.V., Meoni P., et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002, 36:209-217.
119. Montgomery S.A., Tobias K., Zornberg G.L., et al. Efficacy and safety of pregabalin in the treatment of GAD: a six week, multicenter, randomized, double-blind comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006, 67:771-782.
120. Munk-Jørgensen P., Allgulander C., Dahl A.A., et al. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006, 57:1738-1744.
121. Nicholson A., Fuhrer R., Marmot M. Psychological distress as a predictor of CHD events in men: the effect of persistence and components of risk. Psychosom Med 2005, 67:522-530.
122. Nitschke J.B., Sarinopoulos I., Oathes D.J., et al. Anticipatory activation in the amygdala and anterior cingulated in generalized anxiety disorder and prediction of treatment response. Am J Psychiatry 2009, 166:302-310.
123. Noyes R., Clarkson C., Crowe R.R., et al. A family study of generalized anxiety disorder. Am J Psychiatry 1987, 144:1019-1024.
124. Noyes R., Woodman C., Garvey M.J., et al. Generalized anxiety disorder vs. panic disorder: distinguishing characteristics and patterns of comorbidity. J New Ment Dis 1992, 180:369-379.
125. Nutt D.J. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 2001, 62:22-27.
126. Otto M.W., Simon N.M., Wisniewski S.R., et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 2006, 189:20-25.
127. Pandina G.J., Canuso C.M., Turkoz I., et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull 2007, 40:41-57.
128. Patchev V.K., Shoaib M., Holsboer F., et al. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience 1994, 62:265-271.
129. Patchev V.K., Montkowski A., Rouskova D., et al. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxycorticosterone (TH DOC) abolishes the behavioral and neuroendocrine consequences of adverse early life events. J Clin Invest 1997, 99:962-966.
130. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J 1992, 6:2311-2322.
131. Pérez-Edgard K., Bar-Haim Y., McDermott J.M., et al. Variations in the serotonin-transporter gene are associated with attention bias patterns to positive and negative emotions faces. Biol Psychol 2010, 83:269-271.
132. Perlis R.H., Ostacher M.J., Patel J.K., et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006, 163:217-224.
133. Pollack M.H., Simon N.M., Zalta A.K., et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006, 59:211-225.
134. Pollack M.H., Tiller J., Xie F., et al. Tiagabine in adult patients with generalized anxiety disorder. Results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008, 28:308-316.
135. Porenski E.K., Dew M.A., Karp J.F., et al. The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and health care utilization. Am J Geriatr Psychiatry 2009, 17:473-482.
136. Power K.G., Simpson R.J., Swanson V., et al. A controlled comparison or cognitive behaviour therapy, diazepam and placebo, alone and in combination for treatment of generalised anxiety disorder. J Anxiety Disord 1990, 4:267-292.
137. Raskin M., Peeke H.V.S., Dickman W., et al. Panic and generalized anxiety disorder: developmental antecedents and precipitants. Arch Gen Psychiatry 1982, 39:687-689.
138. Reynolds C.F., Shaw D.H., Newton T.F., et al. EEG sleep in outpatients with generalized anxiety disorder: a preliminary comparison with depressed outpatients. Psychiatry Res 1983, 8:81-89.
139. Rickels K., Morris R.J., Newman H., et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol 1983, 23:234-242.
140. Rickels K., Downing R., Schweizer E., et al. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993, 50:884-895.
141. Rickels K., Pollack M.H., Feltner D.E., et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005, 62:1022-1030.
142. Rihmer Z., Szádóczky E., Füredi J., et al. Anxiety disorders comorbidity in bipolar I, bipolar II and unipolar major depression: results from a population-based study in Hungary. J Affect Disord 2001, 67:175-179.
143. Rocca P., Beoni A.M., Eva C., et al. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol Psychiatry 1998, 43:767-773.
144. Rogers M.P., White K., Warshaw M.G., et al. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatry Med 1994, 24:83-96.
145. Rosenbaum A.H., Schatzberg A.F., Jost F.A., et al. Urinary free cortisol levels in anxiety. Psychosomatics 1983, 24:835-837.
146. Roy-Byrne P.P., Katon W. Generalized anxiety disorder in primary care: the precursor/modifier pathway to increased health care utilization. J Clin Psychiatry 1997, 58:34-38.
147. Saletu-Zyhlarz G., Saletu B., Anderer P., et al. Nonorganic insomnia in generalized anxiety disorder. Controlled studies of sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neurophysiology 1997, 36:117-129.
148. Schneider L.S., Munjack D., Severson J.A., et al. Platelet [3H] imipramine binding in GAD, panic disorder, and agoraphobia with panic attacks. Biol Psychiatry 1987, 22:59-66.
149. Senkowski D., Linden M., Zubrägel D., et al. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. Biol Psychiatry 2003, 53:304-314.
150. Sevy S., Papadimitriou G.N., Surmont D.W., et al. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989, 25:141-152.
151. Sheehan D.V. The Worry Anxiety Tension Scale (WAT) for tracking outcomes in generalized anxiety disorder (GAD) 2000, Copyright.
152. Sheehan D., Raj A. Benzodiazepines. The American Psychiatric Publishing Textbook of Psychopharmacology 1991, 465-486. The American Psychiatric Publishing Inc., Arlington, VA. 4th ed. A. Shatzberg, C. Nemeroff (Eds.).
153. Sheehan D.V., Sheehan K.H. Current approaches to the pharmacologic treatment of anxiety disorders. Psychopharmacol Bull 2007, 40:98-109.
154. Sheehan K.H., Sheehan D.V. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 2008, 23:70-83.
155. Sheehan D.V., Raj B.A., Sheehan K.H., et al. The relative efficacy of high dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993, 88:1-11.
156. Sheehan D.V., Lecubrier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-33.
157. Sheehan D.V., McElroy S.L., Harnett-Sheehan K., et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 2009, 115:376-385.
158. Simon N.M., Otto M.W., Wisniewski S.R., et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004, 161:2222-2229.
159. Simon N.M., Connor K.M., LeBeau T.R.T., et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008, 197:675-681.
160. Smith S.S., Gong Q.H., Hsu F.C., et al. GABAA receptor α4 subunit suprpression prevens withdrawal properties of an endogenous steroid. Nature 1998, 292:926-930.
161. Snaith R.P., Baugh S., Clayden A., et al. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982, 141:518-523.
162. Stein M.B., Heimberg R.G. Well-being and life satisfaction in generalized anxiety disorder: comparison to major depressive disorder in a community sample. J Affect Disord 2004, 79:161-166.
163. Stein D.J., Ahokas A.A., de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder. A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28:561-566.
164. Stocchi L., Nelson H., Sargent D.J., et al. Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001, 19:3895-3902.
165. Thayer J.F., Friedman B.H., Borkovec T. Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996, 39:255-266.
166. The ESEMeD/MHEDEA 2000 Investigators Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004, 109:21-27.
167. Thomason M.E., Henry M.L., Hamilton J.P., et al. Neural and behavioral response to threatening faces in children as function of the short allele of the serotonin transporter gene. Biol Psychol 2010, 85:38-44.
168. Thyer B.A., Parrish R.T., Curtis G.C., et al. Ages of onset of DSM-III anxiety disorders. Comp Psychiatry 1985, 26:113-122.
169. Tiihonen J., Kuikka J., Rasanen P., et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 1997, 2:463-471.
170. Tiller J.W.G., Biddle N., Maguire K.P., et al. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 1988, 23:261-270.
171. Tillfors M., Furmark T., Marteinsdottir I., et al. Cerebral blood flow during anticipation of public speaking in social phobia: A PET study. Biol Psychiatry 2002, 52:1113-1119.
172. Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry 1983, 40:1085-1089.
173. Wacker H.R., Mullejans R., Klein K.H., et al. Identification of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-III-R using the Composite International Diagnostic Interview (CIDI). Int Methods Psychiatr Res 1992, 2:91-100.
174. Weizman R., Tanne Z., Granek M., et al. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 1987, 138:289-292.
175. Whalen P.J., Johnstone T., Somerville L.H., et al. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry 2008, 63:858-863.
176. Wittchen H.U., Zhao S., Kessler R.C., et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:355-364.
177. Wittchen H.U., Boyer P. Sensitivity and specificity of the Anxiety Screening Questionnaire (ASQ-15). Br J Psychiatry 1998, 173:10-17. Screening for anxiety disorders.
178. Wittchen H.U., Kessler R.C., Beesdo K., et al. Generalized anxiety disorder and depression in primary care: prevalence, recognition and management. J Clin Psychiatry 2002, 63:24-34.
179. International Statistical Classification of Diseases and Related Health Problems 1992, World Health Organization, World Health Organization, Geneva. 10th revision.
180. Wu J.C., Buchsbaum M.S., Hershey T.G., et al. PET in generalized anxiety disorder. Biol Psychiatry 1991, 29:1181-1199.
181. Yonkers K.A., Warshaw M.G., Massion A.O., et al. Phenomenology and course of generalized anxiety disorder. Br J Psychiatry 1996, 168:308-313.
182. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983, 67:361-370.